Yelena Janjigian
MD
Chief, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center

Yelena Y. Janjigian MD, is Professor and Chief of Gastrointestinal (GI) Oncology Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). Her research career and clinical practice are focused on improving treatment outcomes for patients with GI malignancies. She is an international expert in the management of cancers of esophagus and stomach and lead several seminal studies that changed practice and set the standard of care for these diseases. She produced high impact publications describing the genomic basis for esophagogastric cancer pathogenesis and secure federal grants to fund future studies. Her research is focused on developing new treatments, with a special emphasis on defining the therapeutically relevant molecular characteristics of tumors in the GI tract, with 120 peer-reviewed publications to date.

Dr. Janjigian received her BS from the University of California, San Diego and her MD from the New York University School of Medicine. She did her internal medicine residency at New York School of Medicine/Bellevue Hospital and her hematology/oncology fellowship training at MSKCC. She joined the MSK faculty in 2009 as a member of the GI Oncology Service.

Dr. Janjigian is an active member of American Society of Clinical Oncology (ASCO), American Association of Cancer Research (AACR) and European Society for Medical Oncology (ESMO) holding an array of leadership positions. As Chief of the GI Oncology Service, Dr. Janjigian’s mission is to foster research and innovation that transform the future of GI oncology to help patients worldwide

Sessions

Register
General Session

State-of-the-Art Management of Localized GEJ Cancer: Neoadjuvant Therapy vs Adjuvant Therapy

Saturday, March 22, 2025
10:35 AM - 11:20 AM
General Session

HER2 as a Therapeutic Target in Metastatic Biliary Tract Cancer and Gastroesophageal Adenocarcinoma: Recent Advances and Future Directions

Saturday, March 22, 2025
12:05 PM - 12:35 PM
General Session

Evaluating CRC Screening Options: Colonoscopy vs Biomarker-Based Testing

Saturday, March 22, 2025
1:40 PM - 2:25 PM
General Session

Gastrointestinal Cancers Roundtable

Saturday, March 22, 2025
4:00 PM - 5:00 PM
General Session

Is There a Role for Liver-Directed Therapy in Surgically Unresectable mCRC? Chemotherapy vs Liver-Directed Therapy

Sunday, March 23, 2025
10:35 AM - 11:20 AM
General Session

Optimal Frontline Therapy and Sequencing in Advanced HCC: VEGF Inhibition with ICI vs Dual Immune Checkpoint Blockade?

Sunday, March 23, 2025
1:40 PM - 2:25 PM
General Session

Gastrointestinal Cancers Roundtable

Sunday, March 23, 2025
2:25 PM - 3:25 PM